US Justice Department Reschedules FDA-Approved and Licensed Medical Marijuana Products to Schedule III
The US Department of Justice and Drug Enforcement Administration announced the immediate reclassification of FDA-approved products containing marijuana and marijuana products regulated by state-issued medical licenses to Schedule III of the Controlled Substances Act. This action aligns with President Trump's Executive Order dated December 18, 2025, aimed at enhancing medical marijuana and cannabidiol research.
Alongside this reclassification, the agencies initiated an expedited administrative hearing process scheduled to commence on June 29, 2026. This hearing will evaluate the broader potential rescheduling of marijuana from its current Schedule I classification to Schedule III.
These measures provide immediate clarity for medical researchers, patients, and healthcare providers by formally recognizing certain marijuana-based products as less restricted. The Department maintains strict federal controls to prevent illicit trafficking while promoting medical research.
No details of direct operational impacts or changes to enforcement mechanisms beyond the scheduling and hearing process were provided.
